Synthetic Design Lab reveals first logic-gated ADC at AACR 2026 with ≥10x enhanced targeted cancer cell killing
Synthetic Design Lab, an emerging innovator in the field of antibody-drug conjugates (ADCs) and advanced protein engineering, has unveiled compelling preclinical findings that could redefine how targeted cancer therapies are designed and deployed. Presented during an oral session at the American Association for Cancer Research Annual Meeting 2026, the data mark the company’s first public disclosure of its proprietary SYNTHBODY™ platform, along with early results from its lead therapeutic candidates. The presentation introduces a fundamentally new conceptual and technological framework for biologic drug development—one that integrates programmable logic into protein therapeutics to enhance targeting precision, adaptability, and efficacy.
A Shift Beyond Conventional ADC Design
Traditional ADCs have transformed oncology by enabling targeted delivery of cytotoxic payloads to cancer cells, thereby improving therapeutic index compared to conventional chemotherapy. However, most currently approved ADCs rely on mono-specific or, at best, bispecific antibody architectures. These approaches are inherently constrained by the requirement for a single highly expressed tumor-associated antigen, limiting their applicability across diverse tumor types.
Synthetic Design Lab’s SYNTHBODY™ platform is designed to overcome these limitations by leveraging engineered multi-protein binding architectures. Rather than targeting a single antigen, SYNTHBODY™ therapeutics simultaneously engage multiple cell surface markers, dynamically adjusting their binding interactions based on the molecular context of individual cancer cells. This combinatorial targeting strategy allows the platform to effectively “construct” a synthetic target profile that mimics the high expression and specificity seen in rare cases like HER2-positive cancers.
Unlike conventional biologics that passively bind to a receptor and either block or activate signaling pathways, SYNTHBODY™ molecules function more like molecular decision-making systems. They incorporate built-in logic gates that enable context-dependent behavior, allowing the therapeutic to modulate its activity based on the combination and density of antigens encountered. This capability represents a major departure from static drug-target interactions, introducing an adaptive dimension to biologic therapy.
Introducing Programmable Drug Intelligence
According to Daniel S. Chen, M.D., Ph.D., founder and CEO of Synthetic Design Lab, the SYNTHBODY™ platform signals the emergence of “intelligent” therapeutics. He emphasized that modern drug development has long been guided by the principle of matching the right drug to the right patient—a paradigm that relies heavily on biomarker stratification.
However, Chen suggests that this model could be fundamentally disrupted by drugs capable of adapting themselves to heterogeneous disease biology. “Smart drugs that can adjust their own behavior may eliminate the need for strict patient-drug matching,” he explained. “Instead of tailoring therapies to patients, we may be able to design therapies that tailor themselves to the disease environment.”
This notion of intrinsic drug intelligence has not previously been realized in approved medicines. The SYNTHBODY™ platform represents the first demonstration, at least in preclinical settings, that such adaptability can be engineered into protein-based therapeutics.
Addressing a Core Limitation in Oncology Targeting
One of the most persistent challenges in oncology drug development is the scarcity of tumor-specific antigens that are both highly expressed and selectively localized to cancer cells. The success of ADCs such as trastuzumab deruxtecan has demonstrated the power of precise targeting. In HER2-positive breast cancer, ENHERTU has achieved notable clinical outcomes, including complete response rates exceeding 20% and prolonged durability of response.
However, HER2 represents an exception rather than the rule. Most tumor-associated antigens are expressed at lower levels or are also present on normal tissues, increasing the risk of off-target toxicity and limiting therapeutic efficacy. This constraint has significantly narrowed the range of cancers amenable to current ADC approaches.
SYNTHBODY™ technology addresses this issue by integrating multiple lower-expression targets into a unified targeting strategy. By coordinating interactions with several antigens simultaneously, the platform effectively creates a high-specificity, high-avidity binding profile that would not be achievable through single-target approaches. This synthetic targeting paradigm expands the potential applicability of ADCs across a broader spectrum of malignancies.
Preclinical Data in Multiple Myeloma
At AACR 2026, Synthetic Design Lab presented detailed data on a SYNTHBODY™ construct designed to target multiple myeloma. This molecule incorporates engineered binding domains for three clinically relevant antigens: BCMA, GPRC5D, and CD38. Individually, each of these targets lacks the expression characteristics needed for optimal ADC performance. However, when combined within the SYNTHBODY™ architecture, they produce a synergistic targeting effect.
The results from head-to-head comparisons were striking. The SYNTHBODY™ candidate demonstrated more than a 30-fold increase in internalization compared to belantamab, a BCMA-targeting monoclonal antibody. When conjugated to the cytotoxic payload MMAF, the molecule achieved over 80-fold greater potency than belantamab mafodotin in human myeloma cell lines.
Importantly, the therapeutic maintained robust activity across cell lines with varying expression levels of BCMA, GPRC5D, and CD38. This suggests that the platform can effectively adapt to heterogeneous tumor environments—a critical advantage in cancers like multiple myeloma, where antigen expression can vary significantly between patients and even within the same tumor.
Another notable finding was the molecule’s ability to overcome resistance mechanisms associated with soluble BCMA. Elevated levels of soluble BCMA in circulation are known to interfere with the efficacy of BCMA-targeting therapies. The SYNTHBODY™ construct demonstrated resilience against this challenge, maintaining activity even in the presence of clinically relevant concentrations of soluble antigen.
In Vivo Performance and Pharmacokinetics
Beyond in vitro potency, the SYNTHBODY™ platform also showed promising in vivo characteristics. In mouse tumor models, the multiple myeloma-targeting construct achieved at least a 10-fold increase in potency compared to an IgG-based comparator. Additionally, the platform demonstrated tunable pharmacokinetics resembling those of conventional IgG antibodies, suggesting that it can be optimized for desirable exposure and distribution profiles.
The ability to fine-tune pharmacokinetics is particularly important for ADC development, as it influences both efficacy and safety. By retaining IgG-like behavior while introducing advanced targeting capabilities, SYNTHBODY™ therapeutics may offer a balanced profile suitable for clinical translation.
Expansion into Other Indications
Synthetic Design Lab also reported early-stage data from a SYNTHBODY™ construct targeting Non-Hodgkin’s lymphoma (NHL), which showed similarly encouraging activity. While details remain preliminary, these findings indicate that the platform’s advantages may extend beyond hematologic malignancies.
To accelerate development across multiple cancer types, the company has established a high-throughput engineering system known as SYNTHBODY ENGINE™. This platform enables rapid generation, screening, and optimization of SYNTHBODY™ constructs, facilitating the exploration of diverse target combinations and tumor indications. Early efforts are already underway to develop candidates for solid tumors, a domain where conventional ADCs have faced significant challenges.
A New Paradigm: Logic-Gated Therapeutics
Perhaps the most groundbreaking aspect of the SYNTHBODY™ platform is its incorporation of logic-gated functionality. These constructs operate analogously to electronic circuits, using “AND-BETTER” logic to enhance specificity and activity only when multiple conditions are met. Additional “AND” safety gates help minimize off-target effects, while “MULTIPLIER” functions amplify therapeutic responses through synergistic interactions.
This multi-layered logic system allows SYNTHBODY™ molecules to behave like molecular transistors, processing biological inputs and producing controlled outputs. Such capabilities have no precedent in protein-based medicine and represent a significant step toward programmable therapeutics.
Manufacturing and Developability
Despite their complexity, SYNTHBODY™ constructs have demonstrated favorable manufacturability. The company reported successful production in Chinese hamster ovary (CHO) cells, the industry standard for biologics manufacturing. Additionally, the molecules exhibit strong developability characteristics, including stability and scalability, which are critical for advancing into clinical development.
Scientific Perspective
Ramesh Baliga, Ph.D., co-founder and Chief Scientific Officer of Synthetic Design Lab, highlighted the broader implications of the platform. He noted that SYNTHBODY™ represents a fundamentally new way of conceptualizing cancer targeting—not just by identifying the right antigen, but by engineering the spatial and biophysical properties of the targeting system itself.
By controlling molecular geometry and interaction dynamics, the platform enables emergent properties that cannot be achieved with traditional IgG-based formats. This opens the door to a new class of biologics with capabilities that extend far beyond current therapeutic paradigms.
While the data presented at AACR 2026 are preclinical, they offer a compelling glimpse into the future of targeted cancer therapy. If validated in clinical studies, SYNTHBODY™ therapeutics could significantly expand the reach of ADCs, improve outcomes across a wider range of cancers, and introduce a new generation of adaptive, intelligent medicines.
The journey from preclinical promise to clinical reality remains complex and uncertain. However, Synthetic Design Lab’s early results suggest that the integration of engineering principles, computational design, and molecular biology may unlock new possibilities in oncology—potentially reshaping how drugs are designed, developed, and deployed in the years to come.
About Synthetic Design Lab
Synthetic Design Lab is built to revolutionize antibody-drug conjugates (ADCs) and biologic therapeutics with its novel and proprietary SYNTHBODY™ therapeutic protein platform. Through a focus on control of biophysics, architecture, geometry, and biologically determined patterns and protein communities, the platform is engineered to optimize targeted payload delivery ≥10x compared to current ADCs, potentially improving upon the efficacy, safety, and overall versatility of earlier ADCs.
Source Link:https://www.businesswire.com/
